Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ029
- Development stage
- Preclinical
- Lead developer
- Tuojie Biotech
- Modality
- Small Molecules
01
Overview
TJ029 is a small molecule drug candidate being developed by Tuojie Biotech (Shanghai Tuojie Biotech), a biotechnology company focused on innovative small molecule and small nucleic acid therapies, often in collaboration with or as a subsidiary of Hengrui Medicine. TJ029 is currently in the pipeline for the treatment of various tumors. While the specific biological target has not been publicly disclosed in the primary pipeline table, Tuojie Biotech's oncology portfolio includes inhibitors of targets such as CDK7, CDK2, MALT1, and SHP2. The drug is part of Tuojie's internal development program aimed at addressing unmet needs in oncology.
Beyond the preview
Go deeper on TJ029.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ029.